Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: a prospective cohort study

Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: a prospective cohort study - Portal hemodynamic effects of lenvatinib

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033023

Enrollment

Registered

2018-06-17

Start date

2018-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with advanced hepatocellular carcinoma

Interventions

Lenvatinib 12mg per day for 2 weeks (BW &gt

60) Lenvatinib 8mg per day for 2 weeks (BW &lt

60)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Advanced-stage HCC is confirmed by clinical analysis. 2) BCLC stage B2 or B3

Exclusion criteria

Exclusion criteria: 1)Tumor invasion in intrahepatic large vessels (Vp4) 2)hepatic encephalopathy, refractory ascites 3)hypertension (160/100 or higher.) 4)Severe renal function(eGFR<50ml/min)

Design outcomes

Primary

Measure	Time frame
Changes in portal venous area	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology, Internal Medicine

kiruha@kitasato-u.ac.jp+81-42-778-7750

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026